# Iambic Therapeutics Prices $150 Million IPO at $16 Per Share

- URL: https://stocks.freetheai.org/news/iambic-therapeutics-prices-150-million-ipo-at-16-per-share-798c7f
- Published: 2026-10-14T22:52:00Z
- Category: ipo; sentiment: neutral; impact: medium
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Iambic Therapeutics, Inc. (IAM) has priced its initial public offering at $16 per share, offering 9,375,000 shares of common stock. The company expects to generate $150.0 million in gross proceeds before underwriting discounts and commissions. Shares are scheduled to begin trading on the Nasdaq stock exchange on October 15, 2026, under the ticker symbol IAM.

The public listing marks the biotechnology company's transition from private funding to public equity markets. Proceeds from the offering will provide capital to support and advance the development of its artificial intelligence-driven drug pipeline. Additionally, underwriters have been granted a 30-day option to buy up to 1,406,250 additional shares at the initial public offering price.

Investors will monitor how the stock performs during its market debut and whether underwriters exercise the option for additional shares, which would add up to roughly 15% more stock supply. Subsequent progress and updates from its clinical pipeline will also serve as critical post-IPO catalysts.

## Key points

- Iambic Therapeutics priced 9,375,000 shares at $16 each to raise $150 million in gross proceeds.
- Shares are scheduled to start trading on the Nasdaq under ticker symbol IAM on October 15, 2026.
- Proceeds will help fund the growth and clinical advancement of the company's AI-driven drug pipeline.
- Underwriters hold a 30-day option to buy up to 1,406,250 additional shares at the IPO price.

## Questions and answers

### What is the IPO price for Iambic Therapeutics?

Iambic Therapeutics priced its initial public offering at $16 per share for 9,375,000 shares, bringing expected gross proceeds to $150 million.

### What is the stock ticker for Iambic Therapeutics?

The company will trade on the Nasdaq stock exchange under the ticker symbol IAM starting October 15, 2026.

### How will Iambic Therapeutics use its IPO proceeds?

The gross proceeds of $150 million will provide capital runway to fund the development of its AI-driven drug pipeline.